Subscribe to Updates in Technology, Media & Telecom

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Drug Development Software Experts(?)

Council Members in this Study Group: 22

This study group may include experts knowledgeable on topics such as IT Services, consumer electronics, wireless devices, software, hardware, information technology, semiconductors, media, cable, satellite, internet, broadband, global positioning systems, advertising, online media, telecommunications, networking, wireless, and data storage, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

What is a GLG Leader?
Eric Gruff, PhD MBA, Principal, E4 ConsultingEric Gruff, PhD MBA
Principal
E4 Consulting

Eric Gruff, PhD, MBA, BS, is the Founder of E4 Consulting, which specializes in pharmaceutical development, regulatory affairs, and project and portfolio management. Dr. Gruff has over 16 years of experience in the pharmaceutical and biotech sector, including leadership roles at Pfizer, Agouron Pharmaceuticals,...

Roger Wallhouse, Chairman, Health Systems Solutions LtdRoger Wallhouse
Chairman
Health Systems Solutions Ltd

Roger Wallhouse is the Founder/Managing Partner at Health Systems Solutions Ltd, United Kingdom, a company providing strategic business services to healthcare organizations and focusing on market entry, company and product positioning, and governmental introductions. He has over 30 years of experience...

Mark Capriani, MBA
President and Chief Executive Officer
AciesHealth

Mark Capriani, MBA, is the President and Chief Executive Officer of AciesHealth, a specialty pharmaceutical company in Pennsylvania. He has over 15 years of experience in pharmaceutical industry including biotech, branded and multi source pharmaceuticals, consumer products, device, and wound and burn...

GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Tainted Heparin Will Mean More Scrutiny of Drug Manufacturers | 04-21-2008
Author: Eric Gruff, PhD MBA, Principal, E4 Consulting

Regardless of the reason (greed, carelessness, incompetence, etc.) that Chinese heparin became tainted, the end result will be increased scrutiny on imported raw materials and other ingredients, not only from China, but from all 3rd World suppliers. How the FDA and other regulatory agencies actually...

AtheroGenics' AGI-1067 Shows Some Promise, But There Are Still Questions | 04-16-2008
Author: Eric Gruff, PhD MBA, Principal, E4 Consulting

The 3-month reduction in HbA1c demonstrated by AGI-1067 is promising, but I still have many questions regarding the design and outcomes. There are many existing therapies that lower A1c - many have undesireable side effects like weight gain or hepatotoxicity.

Cubist's Antibiotic Cubicin is Tainted: A Mess Not of Their Doing? Maybe, Maybe Not. | 04-14-2008
Analysis of: Cubist Finds Its Antibiotic Cubicin Is Tainted | online.wsj.com
Author: Eric Gruff, PhD MBA, Principal, E4 Consulting

The news that Cubist's Cubicin has been contaminated with 2-mercaptobenzothiazole (MBT) has caused great concern for patients. It appears that the MBT has leeched out of the Cardinal Health ReadyMED drug pumps that are used for delivering Cubicin. Regardless of who is at fault, everyone involved (Cubist,...

Insurers Should be the First Line of Defense Against Vytorin | 04-08-2008
Analysis of: Will Insurers Reduce Coverage For Vytorin? | www.pharmalot.com
Author: Eric Gruff, PhD MBA, Principal, E4 Consulting

The pharmaceutical industry continues to lay its collective head on the chopping block by pushing drugs like Vytorin that demonstrate at best marginal activity. Insurers have a fiduciary duty to push back against the poor judgement of drugmakers who take advantage of confusion and DTC advertising to...

Pfizer's Melanoma Treatment Setback Has Bigger Implications | 04-08-2008
Author: Eric Gruff, PhD MBA, Principal, E4 Consulting

While disappointing for patients and caregivers, Pfizer's loss of a late-stage treatment for melanoma casts an even darker shadow on the ability of pharmaceutical and biotech companies to successfully bring new treatments to market. Coupled with other recent Phase 3 failures, this latest outcome points...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Pharmaceutical Software, IT & Other
  • Consultancy, Pharma-Focused
  • Pharmaceuticals/Biotechnology Research Services
  • Pharmaceuticals Manufacturer
  • Biotechnology Manufacturer
  • Academic Institution*
  • Individual/Small Consultancy
  • Other Healthcare Information Technology Company
  • Strategic Management

Most Common Job Types:

  • Director
  • President
  • Owner
  • Engineer
  • Product/Brand Director
  • System Engineer
  • Manufacturing Director
  • Quality Control Supervisor
  • Chief Executive Officer
  • IT Manager
  • Principal

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics